Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase; it is indicated for use in children with subependymal giant cell astrocytoma. The gene discussed is MTOR; the disease is astrocytoma (excluding glioblastoma).